Celgene (NASDAQ:CELG)

GettyImages_183162370

Large Companies With Fastest Revenue and Earnings Growth in 2015

This year is nearing the halfway mark and analysts are beginning to project their biggest winners and losers on the year. S&P Capital IQ recently released a report regarding the ...
Read Full Story »
biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
biotech

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Combine the upcoming typical summer weakness with howls of a biotech bubble, and the recipe is in place for trouble, even for the top stocks in the industry. In a ...
Read Full Story »
dollar

Is Celgene Stumped on Its Portfolio?

Celgene Corp. (NASDAQ: CELG) released its first-quarter results before the markets opened Thursday. The biotech giant had $1.07 in earnings per share (EPS) on $2.08 billion in revenue. That compared ...
Read Full Story »
biotech

What to Expect From Celgene Earnings

Celgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has consensus estimates of $1.06 in earnings per share (EPS) on ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Celgene Corp. (NASDAQ: CELG) is one of the world's top biotech stocks now, and its market cap is nearly $100 billion. The company has made a new investment in a ...
Read Full Story »
Biotechnology word cloud

Short Sellers Increase Their Bets Against Biotech Stocks

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
research

Major Biotech Is So-So for Short Sellers

The short interest data are out for the March 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Euro

How the Weaker Euro Is Impacting Biotech Earnings

It is no secret that a strong dollar and a weak euro, and foreign currency environment, are acting to hurt U.S. corporate earnings. Many investors might think that biotech earnings ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get More Aggressive on Big Biotech

The short interest data are out for the February 27 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

With the market continuing to grind higher, and the memories of the first time the Nasdaq hit 5,000 getting a fair amount of airplay and commentary, the question for most ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
research

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene Corp. (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid in conjunction with dexamethasone. This would go toward treating patients that ...
Read Full Story »